introduction central retinal vein occlusion crvo retinal vascular disease frequent cause visual morbidity older age group resulting circulatory disturbance trunk central retinal vein near lamina cribrosa addition macular edema intraretinal hemorrhage retinal ischemia occur resulting significantly reduced vision unlike branch retinal vein occlusion brvo difficult identify obstructed site retina crvo believed occlusion occurs inside optic nerve however exact mechanism known pathogenesis disease fully understood likely multifactorial varying according clinical scenario study demonstrated atherosclerotic change artery may result narrowing venous lumen within common adventitial sheath lamina cribrosa opremcak hypothesized neurovascular compression central retinal artery central retinal vein optic nerve head within confined space scleral outlet resulting compartment syndrome occurrence crvo also hypothesized inflammation central retinal peripapillary vein may one cause crvo crvo classified two clinical type non-ischemic crvo ischemic crvo recently anti-vascular endothelial growth factor vegf therapy become gold standard treatment macular edema associated crvo choroid observed precisely enhanced depth imaging spectral-domain optical coherence tomography edi-oct many study conducted evaluate choroidal thickness crvo tsuiki reported thickness choroid significantly greater eye crvo early stage crvo decreased following intravitreal bevacizumab treatment hand demonstrated significant difference choroidal thickness crvo eye normal fellow eye result match change choroidal thickness eye crvo addition knowledge study identified choroidal thickness change year therefore aimed investigate choroidal thickness crvo long period year result study included eye patient crvo average age patient crvo 65.24 11.87 41.5 male table among 73.2 hypertension 47.5 diabetes period month crvo eye significantly lower vision fellow eye intraocular pressure iop significantly different crvo fellow eye time point table central macular thickness cmt crvo eye significantly higher fellow eye baseline month table table baseline demographic patient central retinal vein occlusion eye full size table table best corrected visual acuity iop variance full size table table comparison sfct cmt eye patient crvo eye full size table factor associated sfct sfct decrease multiple linear regression analysis adjustment age gender axial length injection time age associated baseline sfct crvo eye 0.017 standard regression coefficient 0.76 additionally factor could related decrease sfct month compared baseline analyzed none showed statistically significant association crvo eye comparison subfoveal choroidal thickness crvo eye fellow eye crvo eye baseline subfoveal choroidal thickness sfct significantly higher fellow eye 246.49 79.69 vs. 228.51 76.00 0.001 fig however significant difference two group month table crvo eye sfct decreased significantly month compared baseline 0.001 period fellow eye showed significant decrease sfct month compared baseline 0.220 0.107 respectively table figure comparison subfoveal choroidal thickness sfct eye patient crvo normal fellow eye full size image visual acuity subfoveal choroidal thickness initial best-corrected visual acuity bcva degree vision improvement show significant association sfct baseline month month however worse initial vision sfct reduction month compared baseline 0.021 0.017 respectively intravitreal injection time subfoveal choroidal thickness average number injection crvo eye 2.88 2.41 month 4.07 3.77 month thicker baseline sfct tended higher total number injection spearman correlation analysis 0.031 correlation coefficient 0.338 ischemic crvo vs. non-ischemic crvo patient crvo compared based classification ischemic crvo non-ischemic crvo significant difference sfct cmt crvo fellow eye period table table comparison sfct cmt ischemic non-ischemic crvo group full size table discussion crvo eye initial sfct significantly higher fellow eye month sfct crvo significantly reduced difference crvo fellow eye considering crvo eye higher initial sfct greater total number intravitreal injection needed previous study shown sfct eye crvo significantly thicker fellow eye sfct decreased significantly following week anti-vegf treatment contrast claimed significant change sfct following vegf treatment long-standing crvo eye study sfct crvo eye significantly thicker fellow eye baseline sfct crvo eye significantly decreased compared baseline year one explanation result conflict study different phase crvo unlike study study target recent onset crvo hence possible choroidal thickness crvo eye fellow eye differ thickness choroid already decreased longstanding crvo crvo initial cmt cmt year year significantly higher fellow eye considering sfct crvo eye show significant difference fellow eye year choroid remained decreased following anti-vegf treatment however macular edema seemed persist longer period time repeated recurrence study significant correlation cmt sfct baseline reported esen study reported choroidal thickness significantly decreased crvo eye one month receiving anti-vegf injection study average recent injection time month examination 4.86 0.62 9.48 1.40 month respectively therefore temporary decrease thickness doe seem due anti-vegf injection tsuiki speculated hypoxia induced rvo increased vegf resulting dilatation blood vessel increased blood flow increased nitric oxide production vascular permeability resulting increased sfct based expected vegf concentration retina choroid would higher ischemic crvo non-ischemic crvo therefore sfct might thicker ischemic crvo study comparing ischemic non-ischemic crvo difference sfct cmt crvo eye fellow eye previously fen demonstrated vegf concentration aqueous humor significantly higher ischemic crvo ischemic brvo however significant difference sfct two group thus significant difference sfct ischemic crvo non-ischemic crvo ischemic crvo ischemic brvo could anticipated factor vegf could also influence change choroidal thickness moreover although sfct increase vegf concentration increase difference sfct ischemic crvo non-ischemic crvo group may appear choroidal thickness may exceed certain range response vegf study required determine exact mechanism according prior study sfct decreased 1.5–4.1 every year one age central retinal artery occlusion study kim choroidal thickness contralateral eye decreased statistically significantly year 218.4 111.7 vs. 215.4 111.4 0.011 average decrease choroidal thickness similar previous study study decrease choroidal thickness fellow eye significant one year small sample size caused long analysis time might led selection bias automated choroidal volume analysis software developed near future study performed large sample size accurately evaluate change choroidal thickness study several limitation first retrospective study sample size small variance sfct large relatively small number participant included study multicenter study large sample size needed future second study excluded eye underwent prp follow-up order judge effect anti-vegf possibility relatively mild case included third sfct manually measured one subfoveal point objective discrimination measuring choroidal thickness several site measuring choroidal volume manual segmentation choroidal layer would another method nevertheless study provides important information regarding change choroidal thickness crvo long period year conclusion patient unilateral crvo sfct crvo eye baseline significantly thicker fellow eye decreased year showing difference fellow eye method patient study retrospective consecutive case series patient diagnosed treatment-naïve unilateral crvo january september hangil eye hospital inclusion criterion study follows symptomatic crvo retinal hemorrhage retinal edema involved macula foveal thickness greater measured oct initial visit macular edema treated intravitreal bevacizumab intravitreal injection bevacizumab administered manner reported previously patient treated using pro-re-nata regimen diagnosis crvo based finding fundus examination fluorescein angiography crvo non-perfusion area larger disc area fluorescein angiography defined ischemic crvo visual acuity improvement line crvo eye following treatment defined functional responder exclusion criterion study included patient coexisting ocular disease age-related macular degeneration diabetic retinopathy uveitis well eye received focal/grid laser photocoagulation pan-retinal photocoagulation prior intravitreal injection e.g. intravitreal corticosteroid intravitreal anti-vegf agent prior ocular surgery except cataract surgery patient also excluded refractive disorder greater patient chart reviewed following data age sex medical history hypertension diabetes mellitus best-corrected visual acuity bcva axial length measured iol master carl zeiss meditec dublin california usa anti-vegf injection date number intravitreal injection bcva converted logarithm minimum angle resolution logmar bcva iop sfct compared crvo eye fellow eye follow-up visit imaging protocol edi-oct using heidelberg spectralis heidelberg spectral domain optical coherence tomography heidelberg engineering dossenheim germany platform used sfct measured subfoveal point extending outer border pigment epithelium choroidal scleral boundary using built-in caliper software better accuracy horizontal vertical macular b-scans measured choroidal thickness determined average value cmt recorded patient using automated software present 25-line raster scan pattern choroidal thickness cmt measured initial presentation month follow-up crvo fellow eye ethic statement study conducted accordance principle declaration helsinki institutional review board irb hangil eye hospital approved study waived requirement informed consent study participant due retrospective nature study statistical analysis ibm spss statistic 25.0 software window spss chicago illinois usa used data analysis sfct measured crvo fellow eye compared using paired t-test analysis factor related visual acuity improvement performed using spearman correlation analysis comparison ischemic non-ischemic crvo performed using wilcoxon signed-rank test multiple linear regression analysis subsequently performed using forward selection technique identify explanatory variable statistically significant contribution baseline sfct difference considered statistically significant -values 0.05